Dossier assessment
Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Adults with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors |
Result of dossier assessment:
| Added benefit not proven due to lack of suitable study data |
Additional information
Federal Joint Committee (G-BA)
2021.02.18 A G-BA decision was published.
Project details
- Project no.
- A20-75
- Commission
- Commission awarded on 28.08.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Entrectinib (solid tumours with a neurotrophic tyrosine receptor kinase [NTRK] gene fusion, > 1 month to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed